OncoMatch/Clinical Trials/NCT04297605
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
Is NCT04297605 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Pembrolizumab for non-small cell lung cancer.
Treatment: Pembrolizumab — The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIC, IV
Performance status
ECOG 2–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1000/mm3; platelet count ≥100,000/mm3
Kidney function
crcl >50 (if pemetrexed is to be offered)
Liver function
ast and alt ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Rochester · Rochester, New York
- University of Rochester · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify